SB 202190 is a selective, potent, cell-permeable inhibitor of p38 MAP kinases, inhibiting p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively. When tested at 10 μM, SB 202190 has negligible effects on a range of other kinases, including other MAP kinases (ERKs, JNKs). Pyridinyl imidazole inhibitors, including this compound, directly bind p38 MAP kinases in the ATP binding pocket. Recently, SB 202190 has been used to elucidate the roles of p38 MAP kinases in inflammatory cytokine expression, nicotine-induced receptor expression, and HIV-mediated depressive disorder.
SB 202190 is a DFG inhibitor used in the treatment of colorectal cancer. It is a highly selective, potent inhibitor of p38 MAP kinase. SB-202190 is able to promote proliferation of C6 cells in lower concentration but induced apoptosis in higher levels. Studies show that SB202190 can protect neural function from ischemia/reperfusion injury and regulate the activation of Bcl-2 and Bax protein after ischemia/reperfusion in rat.
ChEBI: A member of the class of imidazoles that is 1H-imidazole in which the hydrogens at positions 2, 4, and 5 are replaced by 4-hydroxyphenyl, pyridin-4-yl, and 4-fluorophenyl groups, respectively. It is a widely used inhibitor of mitogen-act
vated protein kinase (MAPK) alpha and beta.
A potent, reversible, competitive, and cell-permeable inhibitor of p38 MAP kinase. Inhibits p38 phosphorylation of myelin basic protein (MBP) with no effect on the activity of the ERK or JNK MAP kinase subgroups. Also inhibits the kinase activity of p38β (K
i = 16 nM; IC
50 = 350 nM) and p38 phosphorylation of activating transcription factor 2 (ATF-2; IC
50 = 280 nM). Blocks LPS-induced TNF-α and interleukin biosynthesis. Reported to induce LDL receptor expression in Hep52 cells. A 1 mg/ml solution of SB 202190 (Cat. No.
559397) in anhydrous DMSO is also available.
A highly selective, potent and cell-permeable inhibitor of p38 MAP kinase. Binds within the ATP pocket of the active kinase (K d = 38 nM, as measured in recombinant human p38), and selectively inhibits the p38 α and β isoforms (IC 50 = 50 and 100 nM at SAPK2a/p38 and SAPK2b/p38 β 2 respectively). Also available as part of the MAPK Inhibitor Tocriset™ .
SB202190, a pyridinyl imidazole, inhibits p38 MAP kinase activity through competition with ATP, and has been shown to induce apoptosis through activation of cysteine protease-like caspases. SB202190 blocks both lipopolysaccharide-induced gene expression and nitric oxide-induced stabilization of interleukin-8 mRNA in monocytes. Pre-treatment of cells with SB202190 has been shown to inhibit phosphorylation of p38 MAPK despite exposure to anisomycin, a known inducer of the MAPK pathway. Of note, the mechanism of inhibition of SB202190 is unlike the one seen with SB203580, which inhibits p38 MAPK catalytic activity by binding to the ATP binding pocket, but does not inhibit phosphorylation of p38 MAPK by upstream kinases.
[1] P R YOUNG. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site.[J]. The Journal of Biological Chemistry, 1997, 272 18: 12116-12121. DOI:
10.1074/jbc.272.18.12116[2] S. DAVIES. Specificity and mechanism of action of some commonly used protein kinase inhibitors.[J]. The Ukrainian Biochemical Journal, 2000, 24 1: 95-105. DOI:
10.1042/bj3510095[3] CARL L. MANTHEY. SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes[J]. Journal of Leukocyte Biology, 1998, 64 3: 409-417. DOI:
10.1002/jlb.64.3.409[4] S NEMOTO. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase.[J]. The Journal of Biological Chemistry, 1998, 273 26: 16415-16420. DOI:
10.1074/jbc.273.26.16415
